Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication

Bernies van der Hiel; Else A Aalbersberg; Alfons J M van den Eertwegh; Jitha Fischer; Ronald Boellaard; Filip Y F L de Vos; Marye J Boers-Sonderen; Marcel P M Stokkel; Linda J de Wit-van der Veen; John B A G Haanen

doi:10.1097/RLU.0000000000005281

Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication

Bernies van der Hiel, Else A Aalbersberg, Alfons J M van den Eertwegh, Jitha Fischer, Ronald Boellaard, Filip Y F L de Vos, Marye J Boers-Sonderen, Marcel P M Stokkel, Linda J de Wit-van der Veen, John B A G Haanen

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose This prospective study evaluates the biodistribution of 18F-FLT PET in patients with advanced melanoma before and after treatment with BRAF/MEK inhibitors. Patients and Methods Eighteen BRAF-positive unresectable stage IIIc or IV melanoma patients referred for 18F-FLT PET/CT before (BL) and during (D14) BRAF/MEK inhibition were included. 18F-FLT accumulation in the liver, bone marrow, blood, and muscle was quantified. Results Baseline interpatient 18F-FLT uptake had a coefficient-of-variation between 17.5% and 21.5%. During treatment, liver uptake increased (SUVmeanBL = 4.86 ± 0.98, SUVmeanD14 = 6.31 ± 1.36, P < 0.001) and bone marrow uptake decreased (SUVmeanBL = 7.67 ± 1.65, SUVmeanD14 = 6.78 ± 1.19, P < 0.025). Both changes were unrelated to baseline metabolic tumor volume or tumor response. Conclusions To assess 18F-FLT PET, both liver and bone marrow uptake may be used as normal tissue references at baseline, but 18F-FLT biodistribution significantly changes in longitudinal response studies when treated with BRAF/MEK inhibitors.

Original language	English
Pages (from-to)	722-726
Number of pages	5
Journal	Clinical Nuclear Medicine
Volume	49
Issue number	8
Early online date	15 May 2024
DOIs	https://doi.org/10.1097/RLU.0000000000005281
Publication status	Published - 1 Aug 2024

Keywords

F-FLT
biodistribution
BRAF mutation
melanoma
targeted therapy

Access to Document

10.1097/RLU.0000000000005281

Cite this

van der Hiel, B., Aalbersberg, E. A., van den Eertwegh, A. J. M., Fischer, J., Boellaard, R., de Vos, F. Y. F. L., Boers-Sonderen, M. J., Stokkel, M. P. M., de Wit-van der Veen, L. J., & Haanen, J. B. A. G. (2024). Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication. Clinical Nuclear Medicine, 49(8), 722-726. https://doi.org/10.1097/RLU.0000000000005281

@article{ccc6b944cc4147299d21ba0d0b271542,

title = "Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication",

abstract = "Purpose This prospective study evaluates the biodistribution of 18F-FLT PET in patients with advanced melanoma before and after treatment with BRAF/MEK inhibitors. Patients and Methods Eighteen BRAF-positive unresectable stage IIIc or IV melanoma patients referred for 18F-FLT PET/CT before (BL) and during (D14) BRAF/MEK inhibition were included. 18F-FLT accumulation in the liver, bone marrow, blood, and muscle was quantified. Results Baseline interpatient 18F-FLT uptake had a coefficient-of-variation between 17.5% and 21.5%. During treatment, liver uptake increased (SUVmeanBL = 4.86 ± 0.98, SUVmeanD14 = 6.31 ± 1.36, P < 0.001) and bone marrow uptake decreased (SUVmeanBL = 7.67 ± 1.65, SUVmeanD14 = 6.78 ± 1.19, P < 0.025). Both changes were unrelated to baseline metabolic tumor volume or tumor response. Conclusions To assess 18F-FLT PET, both liver and bone marrow uptake may be used as normal tissue references at baseline, but 18F-FLT biodistribution significantly changes in longitudinal response studies when treated with BRAF/MEK inhibitors.",

keywords = "F-FLT, biodistribution, BRAF mutation, melanoma, targeted therapy",

author = "{van der Hiel}, Bernies and Aalbersberg, {Else A} and {van den Eertwegh}, {Alfons J M} and Jitha Fischer and Ronald Boellaard and {de Vos}, {Filip Y F L} and Boers-Sonderen, {Marye J} and Stokkel, {Marcel P M} and {de Wit-van der Veen}, {Linda J} and Haanen, {John B A G}",

year = "2024",

month = aug,

day = "1",

doi = "10.1097/RLU.0000000000005281",

language = "English",

volume = "49",

pages = "722--726",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams & Wilkins",

number = "8",

}

van der Hiel, B, Aalbersberg, EA, van den Eertwegh, AJM, Fischer, J, Boellaard, R, de Vos, FYFL, Boers-Sonderen, MJ, Stokkel, MPM, de Wit-van der Veen, LJ & Haanen, JBAG 2024, 'Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication', Clinical Nuclear Medicine, vol. 49, no. 8, pp. 722-726. https://doi.org/10.1097/RLU.0000000000005281

TY - JOUR

T1 - Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma

T2 - Brief Communication

AU - van der Hiel, Bernies

AU - Aalbersberg, Else A

AU - van den Eertwegh, Alfons J M

AU - Fischer, Jitha

AU - Boellaard, Ronald

AU - de Vos, Filip Y F L

AU - Boers-Sonderen, Marye J

AU - Stokkel, Marcel P M

AU - de Wit-van der Veen, Linda J

AU - Haanen, John B A G

PY - 2024/8/1

Y1 - 2024/8/1

N2 - Purpose This prospective study evaluates the biodistribution of 18F-FLT PET in patients with advanced melanoma before and after treatment with BRAF/MEK inhibitors. Patients and Methods Eighteen BRAF-positive unresectable stage IIIc or IV melanoma patients referred for 18F-FLT PET/CT before (BL) and during (D14) BRAF/MEK inhibition were included. 18F-FLT accumulation in the liver, bone marrow, blood, and muscle was quantified. Results Baseline interpatient 18F-FLT uptake had a coefficient-of-variation between 17.5% and 21.5%. During treatment, liver uptake increased (SUVmeanBL = 4.86 ± 0.98, SUVmeanD14 = 6.31 ± 1.36, P < 0.001) and bone marrow uptake decreased (SUVmeanBL = 7.67 ± 1.65, SUVmeanD14 = 6.78 ± 1.19, P < 0.025). Both changes were unrelated to baseline metabolic tumor volume or tumor response. Conclusions To assess 18F-FLT PET, both liver and bone marrow uptake may be used as normal tissue references at baseline, but 18F-FLT biodistribution significantly changes in longitudinal response studies when treated with BRAF/MEK inhibitors.

AB - Purpose This prospective study evaluates the biodistribution of 18F-FLT PET in patients with advanced melanoma before and after treatment with BRAF/MEK inhibitors. Patients and Methods Eighteen BRAF-positive unresectable stage IIIc or IV melanoma patients referred for 18F-FLT PET/CT before (BL) and during (D14) BRAF/MEK inhibition were included. 18F-FLT accumulation in the liver, bone marrow, blood, and muscle was quantified. Results Baseline interpatient 18F-FLT uptake had a coefficient-of-variation between 17.5% and 21.5%. During treatment, liver uptake increased (SUVmeanBL = 4.86 ± 0.98, SUVmeanD14 = 6.31 ± 1.36, P < 0.001) and bone marrow uptake decreased (SUVmeanBL = 7.67 ± 1.65, SUVmeanD14 = 6.78 ± 1.19, P < 0.025). Both changes were unrelated to baseline metabolic tumor volume or tumor response. Conclusions To assess 18F-FLT PET, both liver and bone marrow uptake may be used as normal tissue references at baseline, but 18F-FLT biodistribution significantly changes in longitudinal response studies when treated with BRAF/MEK inhibitors.

KW - F-FLT

KW - biodistribution

KW - BRAF mutation

KW - melanoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85197778904&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000005281

DO - 10.1097/RLU.0000000000005281

M3 - Article

C2 - 38768063

SN - 0363-9762

VL - 49

SP - 722

EP - 726

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 8

ER -

Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this